154 related articles for article (PubMed ID: 38662191)
1. Varenicline Solution Nasal Spray for the Treatment of Dry Eye Disease Following LASIK.
Ferguson TJ; Messer B; Risbrudt N; Stofferahn S; Greenwood M
Ophthalmol Ther; 2024 Jun; 13(6):1693-1701. PubMed ID: 38662191
[TBL] [Abstract][Full Text] [Related]
2. Does Dry Eye Disease Severity Impact Efficacy of Varenicline Solution Nasal Spray on Sign and Symptom Treatment Outcomes?
Sheppard JD; O'Dell LE; Karpecki PM; Raizman MB; Whitley WO; Blemker G; Hemphill M; Hendrix LH; Gibson A; Macsai M
Optom Vis Sci; 2023 Feb; 100(2):164-169. PubMed ID: 36728653
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of Single-dose OC-02 (Simpinicline Solution) Nasal Spray on Signs and Symptoms of Dry Eye Disease: The PEARL Phase II Randomized Trial.
Torkildsen GL; Pattar GR; Jerkins G; Striffler K; Nau J
Clin Ther; 2022 Sep; 44(9):1178-1186. PubMed ID: 35965109
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of OC-01 (Varenicline Solution) Nasal Spray on Signs and Symptoms of Dry Eye Disease: The ONSET-2 Phase 3 Randomized Trial.
Wirta D; Vollmer P; Paauw J; Chiu KH; Henry E; Striffler K; Nau J;
Ophthalmology; 2022 Apr; 129(4):379-387. PubMed ID: 34767866
[TBL] [Abstract][Full Text] [Related]
5. Dry eye disease after refractive surgery: comparative outcomes of small incision lenticule extraction versus LASIK.
Denoyer A; Landman E; Trinh L; Faure JF; Auclin F; Baudouin C
Ophthalmology; 2015 Apr; 122(4):669-76. PubMed ID: 25458707
[TBL] [Abstract][Full Text] [Related]
6. OC-01 (Varenicline Solution) Nasal Spray Demonstrates Consistency of Effect Regardless of Age, Race, Ethnicity, and Artificial Tear Use.
Epitropoulos AT; Daya SM; Matossian C; Kabat AG; Blemker G; Striffler K; Hendrix L; Macsai M; Gibson A
Clin Ophthalmol; 2022; 16():3405-3413. PubMed ID: 36249445
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of bilateral OC-01 (varenicline solution) nasal spray in alleviating signs and symptoms of dry eye disease: A systematic review.
Ballesteros-Sánchez A; Borroni D; De-Hita-Cantalejo C; Sánchez-González MC; Sanchez-Gomez S; Rocha-de-Lossada C; Sánchez-González JM
Cont Lens Anterior Eye; 2024 Feb; 47(1):102097. PubMed ID: 38065797
[TBL] [Abstract][Full Text] [Related]
8. Varenicline solution nasal spray for dry eye disease in Chinese patients: a randomized phase 3 trial.
Tian L; Jin X; Wang J; Xu Y; Lu C; Zhao S; Zhu Q; Dai H; Gu H; Zhang M; Wang L; Lu X; Ma L; Zhu L; Zeng Q; Zhang H; Fu Y; Li S; Tao L; Ren Q; Ding F; Zhang S; Zhu S; Li Z; Jie Y
Lancet Reg Health West Pac; 2024 Apr; 45():101032. PubMed ID: 38440130
[TBL] [Abstract][Full Text] [Related]
9. A phase II randomized trial to evaluate the long-term (12-week) efficacy and safety of OC-01 (varenicline solution) nasal spray for dry eye disease: The MYSTIC study.
Quiroz-Mercado H; Hernandez-Quintela E; Chiu KH; Henry E; Nau JA
Ocul Surf; 2022 Apr; 24():15-21. PubMed ID: 34920097
[TBL] [Abstract][Full Text] [Related]
10. Effects of laser in situ keratomileusis on tear production, clearance, and the ocular surface.
Battat L; Macri A; Dursun D; Pflugfelder SC
Ophthalmology; 2001 Jul; 108(7):1230-5. PubMed ID: 11425680
[TBL] [Abstract][Full Text] [Related]
11. Matching-adjusted indirect comparison of phase 3 clinical trial outcomes of OC-01 (varenicline solution) nasal spray and lifitegrast 5% ophthalmic solution for the treatment of dry eye disease.
White DE; Hendrix LH; Sun L; Tam I; Macsai M; Gibson AA
J Manag Care Spec Pharm; 2023 Jan; 29(1):69-79. PubMed ID: 36030415
[No Abstract] [Full Text] [Related]
12. Autologous serum eye drops for dry eye.
Pan Q; Angelina A; Marrone M; Stark WJ; Akpek EK
Cochrane Database Syst Rev; 2017 Feb; 2(2):CD009327. PubMed ID: 28245347
[TBL] [Abstract][Full Text] [Related]
13. Varenicline Solution Nasal Spray: A Review in Dry Eye Disease.
Frampton JE
Drugs; 2022 Sep; 82(14):1481-1488. PubMed ID: 36197638
[TBL] [Abstract][Full Text] [Related]
14. ONSET-1 Phase 2b Randomized Trial to Evaluate the Safety and Efficacy of OC-01 (Varenicline Solution) Nasal Spray on Signs and Symptoms of Dry Eye Disease.
Wirta D; Torkildsen GL; Boehmer B; Hollander DA; Bendert E; Zeng L; Ackermann M; Nau J
Cornea; 2022 Oct; 41(10):1207-1216. PubMed ID: 36107843
[TBL] [Abstract][Full Text] [Related]
15. The effect of hinge position on corneal sensation and dry eye after LASIK.
Donnenfeld ED; Solomon K; Perry HD; Doshi SJ; Ehrenhaus M; Solomon R; Biser S
Ophthalmology; 2003 May; 110(5):1023-9; discussion 1029-30. PubMed ID: 12750107
[TBL] [Abstract][Full Text] [Related]
16. Combination therapy with 3% diquafosol tetrasodium ophthalmic solution and sodium hyaluronate: an effective therapy for patients with dry eye after femtosecond laser-assisted
Wang T; Di Y; Li Y
Front Med (Lausanne); 2023; 10():1160499. PubMed ID: 37153094
[TBL] [Abstract][Full Text] [Related]
17. Impact of Topical Cyclosporine-A or Topical Chloroquine on Post-LASIK Ocular Surface Stability - A Randomized Controlled Trial.
Titiyal JS; Goswami A; Kaur M; Sharma N; Maharana PK; Velpandian T; Pandey RM
Curr Eye Res; 2023 Jun; 48(6):557-563. PubMed ID: 36800492
[TBL] [Abstract][Full Text] [Related]
18. Bilateral Effect of OC-01 (Varenicline Solution) Nasal Spray for Treatment of Signs and Symptoms in Individuals with Mild, Moderate, and Severe Dry Eye Disease.
Katz J; Periman LM; Maiti S; Sarnicola E; Hemphill M; Kabat AG; Hendrix LH; Shah P; Gibson A
Clin Ther; 2022 Nov; 44(11):1463-1470. PubMed ID: 36763994
[TBL] [Abstract][Full Text] [Related]
19. A Single Administration of OC-01 (Varenicline Solution) Nasal Spray Induces Short-Term Alterations in Conjunctival Goblet Cells in Patients with Dry Eye Disease.
Dieckmann GM; Cox SM; Lopez MJ; Ozmen MC; Yavuz Saricay L; Bayrakutar BN; Binotti WW; Henry E; Nau J; Hamrah P
Ophthalmol Ther; 2022 Aug; 11(4):1551-1561. PubMed ID: 35653029
[TBL] [Abstract][Full Text] [Related]
20. Does Menopausal Status Affect Dry Eye Disease Treatment Outcomes with OC-01 (Varenicline Solution) Nasal Spray? A Post Hoc Analysis of ONSET-1 and ONSET-2 Clinical Trials.
Nijm LM; Zhu D; Hemphill M; Blemker GL; Hendrix LH; Kabat AG; Gibson AA
Ophthalmol Ther; 2023 Feb; 12(1):355-364. PubMed ID: 36401081
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
